… , the interim analysis of which on 153 Caucasian patients was presented in the … III study
evaluating erlotinib versus platinum-based doublet chemotherapy in advanced NSCLC patients …

… ASPIRATION is the first study to our knowledge that confirms the feasibility prospectively
of continuing erlotinib therapy in selected patients following RECIST PD without undue toxic …

… of outcomes in all lines of therapy for patients with non‐small cell lung … in patients enrolled
on the MARQUEE phase III trial of tivantinib plus erlotinib (T+E) versus placebo plus erlotinib (…

… -arm phase I study to incorporate erlotinib into two frequently used chemoradiotherapy
regimens (SWOG9504 18 and CALGB39801 5 ) for unresectable Stage III NSCLC. Erlotinib, an …

… In the pivotal phase III BR.21 global study, erlotinib significantly prolonged overall survival
(… study includes all patients who received erlotinib over a 23-month period, including patients …

… All laboratory analyses in this study were done blinded to patient clinical data. Pretreatment
biomarker expression profiles were compared between responders and non-responders by …

… with the EGFR tyrosine kinase inhibitor erlotinib, in this phase 2 study for recurrent MG patients
( www.ClinicalTrials.gov , NCT00671970). Fifty-seven patients (n = 25, glioblastoma [GBM…

… This multicenter, randomized, phase III study investigated the efficacy of figitumumab plus
erlotinib compared with erlotinib alone in patients with pretreated, nonsmall-cell lung cancer (…

… We prospectively studied the activity of vorinostat plus erlotinib … patients with progression to
tyrosine kinase inhibitors. … a minimum of 12 weeks on erlotinib were included. The maximum …

… This randomised phase III study was conducted to investigate the efficacy of extended
nodal irradiation (ENI) and/or erlotinib in inoperable oesophageal squamous cell cancer (ESCC). …